Matched-case Comparison of Neoadjuvant Chemotherapy in Patients with FIGO Stage IB1-IIB Cervical Cancer to Establish Selection Criteria
Ting Hu,Shuang Li,Yile Chen,Jian Shen,Xiong Li,Kecheng Huang,Ru Yang,Li Wu,Zhilan Chen,Yao Jia,Shaoshuai Wang,Xiaodong Cheng,Xiaobing Han,Zhongqiu Lin,Hui Xing,Pengpeng Qu,Hongbing Cai,Xiaojie Song,Xiaoyu Tian,Hongbing Xu,Jun Xu,Qinghua Zhang,Ling Xi,Dongrui Deng,Hui Wang,Shixuan Wang,Weiguo Lv,Changyu Wang,Xing Xie,Ding Ma
DOI: https://doi.org/10.1016/j.ejca.2012.03.015
IF: 10.002
2012-01-01
European Journal of Cancer
Abstract:Objective: Neoadjuvant chemotherapy (NACT) for cervical cancer still remains controversial. NACT was evaluated to establish selection criteria.Methods: A matched-case comparison was designed for the NACT group (n = 707) and primary surgery treatment (PST; n = 707) group to investigate short-term responses and high/intermediate risk factors (HRFs/IRFs). The 5-year disease-free survival (DFS) and overall survival (OS) rates were stratified by NACT response, HRFs/IRFs, International Federation of Gynecology and Obstetrics (FIGO) stage and tumour size, respectively.Results: The clinical and pathological response rates were 79.3% and 14.9% in the NACT group. In comparison to the PST group, IRFs but not HRFs were significantly decreased (P < 0.05), and the 5-year DFS rate was significantly improved in the NACT group (88.4% versus 83.1%, P = 0.021). Moreover, the 5-year DFS and OS rates were favourably increased in the clinical responders in comparison to the PST group and the clinical non-responders (P < 0.05). Compared to those of clinical non-responders, the 5-year DFS and OS rates of clinical responders, with or without HRFs, were also significantly increased (P < 0.01). In stage IB2, the 5-year DFS and OS rates were significantly increased, whereas operation duration declined in the NACT group (P < 0.05). For patients with stage IB tumours of 2-5 cm, the 5-year DFS and OS rates of clinical responders were significantly improved (P < 0.05).Conclusions: NACT is a suitable option for patients with cervical cancer, especially for NACT responders and patients with stage IB, which provides a new concept of fertility preservation for young patients. (C) 2012 Elsevier Ltd. All rights reserved.